A5061810065- Breast Cancer Treatment Studies
- Cutaneous Melanoma Detection and Management
- Breast Lesions and Carcinomas
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Breast Implant and Reconstruction
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- Nonmelanoma Skin Cancer Studies
- Reconstructive Surgery and Microvascular Techniques
- Cancer and Skin Lesions
- Vascular Tumors and Angiosarcomas
- BRCA gene mutations in cancer
- Salivary Gland Tumors Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Acute Myeloid Leukemia Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Advanced Radiotherapy Techniques
- Cardiac tumors and thrombi
- Clinical practice guidelines implementation
- Digital Imaging in Medicine
- AI in cancer detection
Mayo Clinic in Arizona
2016-2025
Mayo Clinic
2015-2024
Northwestern University
2023-2024
Sahlgrenska University Hospital
2024
University of Southern California
2023
American College of Surgeons
2017-2022
University of Utah
2022
Brooke Army Medical Center
2022
University of Chicago
2022
Williams (United States)
2022
Abstract Globally breast cancer is the leading cause of death among women. The consists epithelium, stroma and a mucosal immune system that make up complex microenvironment. Growing awareness role microbes in microenvironment recently has led to series findings important for human health. microbiome been implicated development progression at variety body sites including stomach, colon, liver, lung skin. In this study, we assessed tissue microbial signatures intraoperatively obtained samples...
Abstract Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) assessed the antiproliferative activity of CDK4/6 inhibitor palbociclib primary cancer as a prelude to adjuvant studies. Experimental Design: Eligible patients with clinical stage II/III ER+/HER2− received anastrozole 1 mg daily for 4 weeks (cycle 0; goserelin if premenopausal), followed by adding (125 on days...
Women diagnosed with cutaneous melanoma have a survival advantage compared to men, which has been hypothesized be due difference in behavior and/or biology (sex hormones). It remains controversial whether this is dependent on age or stage of disease. We sought compare melanoma-specific between females pre, peri, and postmenopausal groups males the same group, adjusting for This retrospective population-based cohort study using Surveillance, Epidemiology, End Results (SEER) database. Patients...
Background Male breast cancer (MBC) is a rare disease for which there limited understanding of treatment patterns and prognostic factors. Methods Men with TNM stage I to III diagnosed between 2004 2014 in the National Cancer Data Base were included. Trends modalities described using average annual percentage change (AAPC) estimated Joinpoint software analysis trends. Kaplan‐Meier curves multivariate Cox proportional hazards regression model used compare survival subgroups identify Results A...
More than 80% of patients who undergo sentinel lymph node (SLN) biopsy have no nodal metastasis. Here we describe a model that combines clinicopathologic and molecular variables to identify with thin intermediate thickness melanomas may forgo the SLN procedure due their low risk
Both targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable drive robust pathologic responses. In NeoACTIVATE (NCT03554083), a Phase II trial, patients with clinically evident resectable melanoma received either 12 weeks neoadjuvant vemurafenib, cobimetinib, atezolizumab (BRAF-mutated, Cohort A, n = 15), or cobimetinib...
Evolution of melanoma from a primary tumor to widespread metastasis is crucially dependent on lymphatic spread. The mechanisms regulating the initial step in metastatic dissemination via regional lymph nodes remain largely unknown; however, evidence supporting establishment pre-metastatic niche evolving. We have previously described dysfunctional immune profile including reduced expression dendritic cell (DC) maturation markers first node draining tumor, sentinel (SLN). Importantly, this...
Abstract Purpose: Hyperactivation of AKT is common and associated with endocrine resistance in estrogen receptor–positive (ER+) breast cancer. The allosteric pan-AKT inhibitor MK-2206 induced apoptosis PIK3CA-mutant ER+ cancer under estrogen-deprived condition preclinical studies. This neoadjuvant phase II trial was therefore conducted to test the hypothesis that adding anastrozole induces pathologic complete response (pCR) PIK3CA mutant Experimental Design: Potential eligible patients...
Phyllodes tumors (PTs) are rare breast neoplasms, which have little granular data on margins. Current guidelines recommend ≥ 1 cm margins; however, recent suggest narrower margins sufficient, and for benign PT, a negative margin may not be necessary.We performed an 11-institution contemporary (2007-2017) review of PT practices. Demographics, surgical, histopathologic were captured. Logistic regression was used to estimate the association select covariates with local recurrence (LR).Of 550...
For patients with sentinel lymph node (SLN)-positive cutaneous melanoma, the Second Multicenter Selective Lymphadenectomy trial demonstrated equivalent disease-specific survival (DSS) active surveillance using nodal ultrasound versus completion dissection (CLND). Adoption and outcomes of in clinical practice adjuvant therapy recipients are unknown.In a retrospective cohort SLN-positive adults treated at 21 institutions Australia, Europe, United States from June 2017 to November 2019, authors...